What is REGN stock price today?

REGN (Regeneron Pharmaceuticals Inc) stock is trading at $781.67 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is REGN stock going up or down today?

REGN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy REGN stock now?

The decision to buy REGN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is REGN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for REGN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is REGN stock overvalued or undervalued?

REGN currently trades at a P/E ratio of 18.59 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if REGN is fairly priced.

What is REGN's P/E ratio?

REGN has a price-to-earnings (P/E) ratio of 18.59, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is REGN's market cap?

REGN (Regeneron Pharmaceuticals Inc) has a market capitalization of $81.49 billion, making it a mid-cap stock.

What is REGN's price to book ratio?

REGN trades at a price-to-book (P/B) ratio of 2.12, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does REGN pay dividends?

Yes, REGN pays dividends with a current yield of 0.00%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is REGN's dividend yield?

REGN's dividend yield is 0.00%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is REGN stock a good long-term investment?

REGN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is REGN's revenue growth rate?

REGN has shown revenue growth of 0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, REGN is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in REGN?

Key risks for REGN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does REGN compare to its competitors?

Compare REGN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize REGN's performance and positioning.

What is REGN's stock price target for 2026?

Our AI model provides price targets for REGN based on fundamental analysis: Bull case $1016.17 (+30%), Base case $898.92 (+15%), Bear case $703.50 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about REGN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for REGN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is REGN's next earnings report?

REGN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

REGN - Regeneron Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$781.67

+$10.88 (+1.41%)

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.

REGN Key Statistics

Market Cap

$81.49B

P/E Ratio

18.59

P/B Ratio

2.12

EPS

$41.47

Dividend Yield

0.00%

Revenue Growth

+0.0%

Profit Margin

0.3%

Employees

15,410

How REGN Compares to Peers

REGN has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

REGN ranks 2nd in profitability among competitors

P/E Rank

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
REGN(This stock)	$81.49B	18.6	0%	0.3%	-
AMGNAmgen Inc	$204.48B	26.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$178.37B	21.2	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$121.95B	31.3	0%	0.3%	vs VRTX
BIIBBiogen Inc	$28.15B	21.8	-0%	0.1%	vs BIIB
MRNAModerna Inc	$20.93B	N/A	-0%	-1.5%	vs MRNA

Regeneron Pharmaceuticals Inc Company Information

Headquarters: New York; U.S.A
Website: www.regeneron.com
Sector: Health Care
Industry: Biotechnology

REGN - Regeneron Pharmaceuticals Inc

About Regeneron Pharmaceuticals Inc

REGN Key Statistics

How REGN Compares to Peers

Regeneron Pharmaceuticals Inc Company Information

REGN Lician Score

REGN Financial Snowflake

Upcoming Events for REGN